Adult Polyglucosan Body Disease (APBD)
https://academic.oup.com/nar/article/53/13/gkaf658/8203452
Adult polyglucosan body disease (APBD) is a rare, inherited neurological disorder that typically begins in adulthood and causes progressive problems with walking, bladder control, and fatigue. APBD is caused by mutations in the GBE1 gene, which encodes the glycogen branching enzyme. When this enzyme does not function properly, abnormal glycogen accumulates in nerve cells, leading to damage over time. In this study, researchers focused on a specific GBE1 mutation located deep within a non-coding (meaning it does not provide information to make proteins) region of the gene, known as an intron. This hidden mutation disrupts normal RNA splicing, which is the process by which genetic instructions are assembled to produce proteins. This results in a defective enzyme. Using advanced techniques such as whole-genome sequencing (WGS) and RNA sequencing, the team precisely defined this complex mutation and how it alters the GBE1 transcript. To correct this error, the researchers designed short synthetic molecules called antisense oligonucleotides (ASOs). These ASOs bind to the faulty RNA and block the aberrant splicing event, restoring the correct RNA and enabling cells to produce more functional enzyme. In patient-derived cell models (fibroblasts), several ASOs successfully corrected the miss-splicing and increased GBE1 enzyme activity to around 75% of normal levels, enough to suggest meaningful therapeutic benefit. This study provides the first proof-of-concept that ASO-based therapy can directly target and correct the underlying genetic defect in APBD. It offers hope for a precise, mutation-specific treatment and demonstrates how similar strategies could be applied to other rare genetic diseases.